Dr. Walsh’s research focuses on outcomes through the execution of randomized controlled trials and longitudinal neurodevelopmental outcomes evaluation. She coordinates outcomes for a randomized controlled trial on the use of inhaled nitric oxide to prevent chronic lung disease in at risk premature infants.

An additional research focus for Dr. Walsh is on the longitudinal neurodevelopmental outcomes of neonates surviving respiratory failure. She is now Principal Investigator of the recently re-funded NICHD Neonatal Research Network, Cleveland site.

Dr. Hack is one of the leading international authorities on the neurodevelopmental outcomes of preterm children, and Director of the High Risk Follow-up Program. Her clinical and epidemiologic research has documented the impact of neonatal intensive care on the cognitive and neurosensory outcomes of progressively smaller and more immature survivors.

As co-director of the High Risk Follow-up Program, Dr. Wilson Costello is studying the epidemiology of cerebral palsy in former preterm infants, and directs the follow-up component of the NICHD Neonatal Research.

Dr. Baley is the Division’s expert on neonatal infections. She is currently looking into the epidemiology of bronchopulmonary dysplasia (BPD) and infections in preterm infants as well as the prophylaxis for respiratory syncytial virus (RSV) infection.

The Neonatal ECMO Program is headed by Dr. Stork, who coordinates intervention, oversees management of all neonatal ECMO patients, and coordinates outcome data pertaining to the neonatal ECMO therapy.